Schizophrenia is a chronic, severe and recurrent brain disorder that requires continuous, long-term treatment
with antipsychotic medication to minimize relapse and provide clinical benefit to patients. For patients with
schizophrenia, non-adherence to medication is a major risk factor for relapse and re-hospitalization. Long-acting
injectable formulations of second-generation antipsychotics (SGAs-LAIs) provide constant medication delivery and the
potential for improved adherence. Currently, three drugs are available for the treatment of schizophrenia, risperidone longacting
injectable, olanzapine pamoate and paliperidone palmitate. Several studies have also demonstrated efficacy and
safety of such drugs in patients with acute schizophrenia. In the present paper the literature on LAI atypical antipsychotics
will be reviewed and practical advice will be given concerning the use of these drugs in the clinical practice.
Keywords: Adherence, efficacy, long-acting, olanzapine pamoate, paliperidone palmitate, risperidone long-acting,
schizophrenia, second-generation antipsychotics, tolerability.
Rights & PermissionsPrintExport
Published on: 18 July, 2013
Page: [256 - 264]